Artificial Intelligence
Global Clinical Microbiology Instruments and Reagents Industry
![](https://roboticulized.com/wp-content/uploads/2021/02/global-clinical-microbiology-instruments-and-reagents-industry.jpg)
New York, Feb. 01, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Clinical Microbiology Instruments and Reagents Industry” – https://www.reportlinker.com/p05957366/?utm_source=GNW Efforts to carry out a complete genome sequencing of SARS-CoV-2 are being ramped up, while the world waits in agony for medical solutions against the infection. Cracking the COVID-19 genome signature is an essential arsenal in the toolkit for diagnostics, vaccine and drug development. With rapid and accurate diagnosis of SARS-CoV-2 expected to assist in the control of the outbreak, microbiology labs worldwide are racing to test billions of samples. The COVID-19 serology race is getting bigger and faster. Serology tests remain important as it supports community surveillance efforts by playing a key role in identifying individuals with past COVID-19 infections. Responding in droves are developers racing to develop new COVID-19 antibody tests, and laboratories preparing to test samples. The U. S. and Europe together account for a major chunk of the global market. Growth in the coming years will stem from developing countries in Asia Pacific, Latin America, and the Middle East, driven by increasing automation and growing use of rapid microbiological tests.
Unprepared for the Current Pandemic, A Wiser World in the Post COVID-19 Era Will Stand Committed to Virology, Research, & Healthcare
The healthcare and medical system in most parts of the world are in crisis after decades of neglect. With the pandemic exposing the under-preparedness of health systems worldwide, the healthcare industry has suddenly emerged into a key focus area. Governments worldwide have voiced plans to strengthen the healthcare system. Already governments have announced budgetary support to strengthen the health system`s response to COVID-19. From stepping up clinical research activities to constructing new hospitals and procuring critical care life support devices, several measures are being implemented. The world will need to double its healthcare coverage in the coming years. Countries worldwide will need to intensify efforts to expand healthcare services and increase spending to least an additional 1.5% to 2.0% of GDP on primary care than current spends to ensure universal health coverage by 2030. The scenario brings good news for the clinical microbiology market as it brings new opportunities for demand growth of instruments and reagents. Asia-Pacific is expected to emerge as the fastest growing market for automated and rapid microbiological tests. Emerging nations, such as China, India, and Brazil, present significant opportunities due to their constantly growing healthcare infrastructure. In the post COVID-19 period, Asia will record growth supported by the rising prevalence of various pathogenic diseases, need to accelerate microbiological testing and discovery of adapting and mutating bacterium. Currently, clinical microbiology is widely used in Asia to identify fungal, bacterial and parasitic infections. Focus on healthcare reforms, emphasis on controlling costs of public hospitals, continuous rise in number of patients at primary healthcare centers, and rapid growth of private hospitals will spur growth of independent clinical diagnostics automation.
Competitors identified in this market include, among others, Read the full report: https://www.reportlinker.com/p05957366/?utm_source=GNW
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1
II. EXECUTIVE SUMMARY II-1
1. MARKET OVERVIEW II-1 2. FOCUS ON SELECT PLAYERS II-11
3. MARKET TRENDS & DRIVERS II-12 4. GLOBAL MARKET PERSPECTIVE II-39 Table 2: Clinical Microbiology Instruments and Reagents Global Table 3: Clinical Microbiology Instruments and Reagents Market Table 4: Instruments World Market by Region/Country in US$ Table 5: Instruments Historic Market Analysis by Region/Country Table 6: Instruments Market Share Breakdown of Worldwide Sales Table 7: Reagents Potential Growth Markets Worldwide in US$ Table 8: Reagents Historic Market Perspective by Region/Country Table 9: Reagents Market Sales Breakdown by Region/Country in Table 10: Respiratory Diseases Geographic Market Spread Table 11: Respiratory Diseases Region Wise Breakdown of Global Table 12: Respiratory Diseases Market Share Distribution in Table 13: Bloodstream Infections World Market Estimates and Table 14: Bloodstream Infections Market Historic Review by Table 15: Bloodstream Infections Market Share Breakdown by Table 16: Gastrointestinal Diseases World Market by Table 17: Gastrointestinal Diseases Historic Market Analysis by Table 18: Gastrointestinal Diseases Market Share Distribution Table 19: Sexually Transmitted Diseases World Market Estimates Table 20: Sexually Transmitted Diseases Market Worldwide Table 21: Sexually Transmitted Diseases Market Percentage Share Table 22: Urinary Tract Infections Market Opportunity Analysis Table 23: Urinary Tract Infections Global Historic Demand in Table 24: Urinary Tract Infections Market Share Distribution in Table 25: Other Disease Areas World Market by Region/Country in Table 26: Other Disease Areas Historic Market Analysis by Table 27: Other Disease Areas Market Share Breakdown of Table 28: Hospitals & Diagnostic Centers Global Market Table 29: Hospitals & Diagnostic Centers Retrospective Demand Table 30: Hospitals & Diagnostic Centers Market Share Breakdown Table 31: Custom Lab Service Providers Demand Potential Table 32: Custom Lab Service Providers Historic Sales Analysis Table 33: Custom Lab Service Providers Share Breakdown Review Table 34: Academic & Research Institutes Worldwide Latent Table 35: Academic & Research Institutes Global Historic Table 36: Academic & Research Institutes Distribution of Global III. MARKET ANALYSIS III-1
GEOGRAPHIC MARKET ANALYSIS III-1
UNITED STATES III-1 Table 38: Clinical Microbiology Instruments and Reagents Market Table 39: United States Clinical Microbiology Instruments and Table 40: United States Clinical Microbiology Instruments and Table 41: Clinical Microbiology Instruments and Reagents Market Table 42: United States Clinical Microbiology Instruments and Table 43: United States Clinical Microbiology Instruments and Table 44: Clinical Microbiology Instruments and Reagents Table 45: Clinical Microbiology Instruments and Reagents Market CANADA III-13 Table 47: Canadian Clinical Microbiology Instruments and Table 48: Clinical Microbiology Instruments and Reagents Market Table 49: Canadian Clinical Microbiology Instruments and Table 50: Canadian Clinical Microbiology Instruments and Table 51: Clinical Microbiology Instruments and Reagents Market Table 52: Canadian Clinical Microbiology Instruments and Table 53: Clinical Microbiology Instruments and Reagents Market Table 54: Canadian Clinical Microbiology Instruments and JAPAN III-22 Table 56: Clinical Microbiology Instruments and Reagents Market Table 57: Japanese Clinical Microbiology Instruments and Table 58: Japanese Market for Clinical Microbiology Instruments Table 59: Clinical Microbiology Instruments and Reagents Market Table 60: Japanese Clinical Microbiology Instruments and Table 61: Japanese Demand Estimates and Forecasts for Clinical Table 62: Japanese Clinical Microbiology Instruments and Table 63: Clinical Microbiology Instruments and Reagents Market CHINA III-33 Table 65: Clinical Microbiology Instruments and Reagents Table 66: Chinese Clinical Microbiology Instruments and Table 67: Chinese Clinical Microbiology Instruments and Table 68: Clinical Microbiology Instruments and Reagents Table 69: Chinese Clinical Microbiology Instruments and Table 70: Chinese Demand for Clinical Microbiology Instruments Table 71: Clinical Microbiology Instruments and Reagents Market Table 72: Chinese Clinical Microbiology Instruments and EUROPE III-43 Table 74: Clinical Microbiology Instruments and Reagents Market Table 75: European Clinical Microbiology Instruments and Table 76: European Clinical Microbiology Instruments and Table 77: Clinical Microbiology Instruments and Reagents Market Table 78: European Clinical Microbiology Instruments and Table 79: European Clinical Microbiology Instruments and Table 80: Clinical Microbiology Instruments and Reagents Market Table 81: European Clinical Microbiology Instruments and Table 82: European Clinical Microbiology Instruments and Table 83: Clinical Microbiology Instruments and Reagents Market Table 84: European Clinical Microbiology Instruments and FRANCE III-58 Table 86: French Clinical Microbiology Instruments and Reagents Table 87: French Clinical Microbiology Instruments and Reagents Table 88: Clinical Microbiology Instruments and Reagents Market Table 89: French Clinical Microbiology Instruments and Reagents Table 90: French Clinical Microbiology Instruments and Reagents Table 91: Clinical Microbiology Instruments and Reagents Table 92: French Clinical Microbiology Instruments and Reagents Table 93: French Clinical Microbiology Instruments and Reagents GERMANY III-67 Table 95: German Clinical Microbiology Instruments and Reagents Table 96: German Clinical Microbiology Instruments and Reagents Table 97: Clinical Microbiology Instruments and Reagents Market Table 98: German Clinical Microbiology Instruments and Reagents Table 99: German Clinical Microbiology Instruments and Reagents Table 100: Clinical Microbiology Instruments and Reagents Table 101: German Clinical Microbiology Instruments and Table 102: Clinical Microbiology Instruments and Reagents ITALY III-76 Table 104: Clinical Microbiology Instruments and Reagents Table 105: Italian Clinical Microbiology Instruments and Table 106: Italian Clinical Microbiology Instruments and Table 107: Clinical Microbiology Instruments and Reagents Table 108: Italian Clinical Microbiology Instruments and Table 109: Italian Demand for Clinical Microbiology Instruments Table 110: Clinical Microbiology Instruments and Reagents Table 111: Italian Clinical Microbiology Instruments and UNITED KINGDOM III-85 Table 113: Clinical Microbiology Instruments and Reagents Table 114: United Kingdom Clinical Microbiology Instruments and Table 115: United Kingdom Market for Clinical Microbiology Table 116: Clinical Microbiology Instruments and Reagents Table 117: United Kingdom Clinical Microbiology Instruments and Table 118: United Kingdom Demand Estimates and Forecasts for Table 119: United Kingdom Clinical Microbiology Instruments and Table 120: Clinical Microbiology Instruments and Reagents SPAIN III-94 Table 122: Spanish Clinical Microbiology Instruments and Table 123: Clinical Microbiology Instruments and Reagents Table 124: Spanish Clinical Microbiology Instruments and Table 125: Spanish Clinical Microbiology Instruments and Table 126: Clinical Microbiology Instruments and Reagents Table 127: Spanish Clinical Microbiology Instruments and Table 128: Clinical Microbiology Instruments and Reagents Table 129: Spanish Clinical Microbiology Instruments and RUSSIA III-103 Table 131: Clinical Microbiology Instruments and Reagents Table 132: Russian Clinical Microbiology Instruments and Table 133: Russian Clinical Microbiology Instruments and Table 134: Clinical Microbiology Instruments and Reagents Table 135: Russian Clinical Microbiology Instruments and Please contact our Customer Support Center to get the complete Table of Contents About Reportlinker __________________________
Laboratories the world over are busy and have been kept open all through the lockdown period as the race to test for infections and develop drugs, diagnostics, and vaccines continues with undiminished fervor. While industrial laboratories were shut down as part of the containment measures, microbiology labs, virology labs, clinical testing labs, research labs and academic labs have been actively involved in the global fight against the pandemic. Against this backdrop, the global market for Clinical Microbiology will reach a projected market size of US6.1 billion by the year 2027, trailing a CAGR of 6.4%. As COVID-19 antiviral drugs and vaccine development intensifies, billions of dollars are being invested in over 100 vaccine candidates forcing labs to work at full and extended capacity. Scientists across the worlds are working away in labs analyzing data and finding newer ways to advance their corona virus research projects. By isolating and differentiating microorganisms, clinical microbiology plays a pivotal role in supporting the global response against COVID-19. The ability to quickly and easily classify a deadly virus like COVID-19 in minutes is of immense importance in planning and mobilizing medical needs.
Impact of Covid-19 and a Looming Global Recession II-1
Exhibit 1: The World of Clinical Microbiology Gains Sudden
Prominence as Scientists Mobilize United Efforts to Find Ways
to Detect, Treat & Vaccinate People Against the Novel
Coronavirus: Global Scale of Daily Testing Vs Confirmed
Cases Per Million II-3
Clinical Microbiology: An Introduction II-3
Outlook: Evolutionary Battle against Microbes Drives Market Future II-4
Instant Detection of Pathogens : A New Epoch in the Fight for
Survival II-5
Reagents Account for Major Share II-6
Asia-Pacific Drives Future Growth II-6
Recent Market Activity II-7
World Brands II-8
Microbiology Laboratories Switch to Automation to Push Yields II-12
Exhibit 2: World Laboratory Automation Market in US$ Billion
for Years 2018, 2020, 2022, 2024 & 2026 II-13
Clinical Microbiology Market Benefits from Digitalization and
Robotization Trend II-14
Integration of Clinical Microbiology with Cloud Computing II-14
Artificial Intelligence Holds Positive Implications for
Automation of Clinical Microbiology II-15
Advancements in Molecular Diagnostics Drive Market Growth II-15
Emerging Technologies in Clinical Microbiology Diagnostics Aim
at Faster Diagnosis II-16
Technological Advances Crucial to Sustain Future Market Growth II-17
Rapid Diagnostics Bring in a Transformation II-18
Automated and Rapid Microbiological Tests Revolutionize
Microbiological Testing II-19
Traditional Rapid Microbiological Tests Make Way for New, Probe
Tests II-20
Antibiotic Resistant Bacteria Throws the Spotlight on Microbial
Testing II-20
Research in Stem Cell Technology, and Regenerative Medicine
Expand Growth Opportunities II-21
Exhibit 3: Stem Cell Banking Global Market Estimates and
Forecasts in US$ Billion: 2020, 2022 & 2024 II-22
Greater Number of Tests for HIV and Sexually Transmitted
Diseases Amplify Growth II-22
Exhibit 4: Global HIV Prevalence: Number of People Living with
AIDs (in Thousands) by Region for 2018 II-23
Exhibit 5: Number of AIDS-Related Deaths (in Thousands) by
Region for 2018 II-24
Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer
Disease II-24
Home HIV Testing Emerges as a Lucrative Option II-25
Increasing Incidence of Infectious Diseases Drives Growth II-25
Exhibit 6: Infectious Diseases Remain Major Cause of Death in
Under Developed Regions: Breakdown of Leading Causes of Death
in Sub-Saharan Africa (in %) II-27
Exhibit 7: Infectious Diseases Related Mortality High Among
Children Below 5 Years: Breakdown of Leading Causes of Death
in Children Below 5 Years (in %) II-28
Increasing Prevalence of Respiratory Infections Drive Growth II-28
Exhibit 8: Global Number of Deaths Caused Due to Communicable
Diseases (In 000s) II-29
Influenza Boosts Rapid Test Prospects II-30
Exhibit 9: Flu Related CDC Estimates from October 2019-April4,
2020 II-30
Rise in Prevalence of COPD Augments Demand II-30
Exhibit 10: Global Prevalence of COPD by Age Group: Percentage
of Men and Women Affected by the Condition II-31
Rise in Pollution Levels Trigger Increase in Respiratory Diseases II-32
Exhibit 11: World Ranking of Most Polluted Countries: 2019 II-33
Exhibit 12: Percentage Share Breakdown of Global Deaths Linked
to Air Pollution II-34
Increase in Healthcare Spending in Emerging Markets to Propel
Demand II-34
Exhibit 13: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023 II-36
Demographic Shifts & Societal Changes Drive Demand for Test
Volumes II-36
Exhibit 14: Elderly Healthcare Expenditure as a % of GDP II-37
Exhibit 15: Global Population Statistics for the 65+ Age Group
in Million by Geographic Region for the Years 2019, 2025, 2035
and 2050 II-38
Exhibit 16: Life Expectancy at Age 60 and 80 Years: (2010-2015),
(2020-2025) & (2045-2050) II-38
Table 1: Clinical Microbiology Instruments and Reagents Global
Market Estimates and Forecasts in US$ Thousand by
Region/Country: 2020-2027 II-39
Retrospective Market Scenario in US$ Thousand by
Region/Country: 2012-2019 II-40
Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS
2027 II-41
Thousand: 2020 to 2027 II-42
in US$ Thousand: 2012 to 2019 II-43
by Region/Country: 2012 VS 2020 VS 2027 II-44
Thousand: 2020 to 2027 II-45
in US$ Thousand: 2012 to 2019 II-46
Percentage: 2012 VS 2020 VS 2027 II-47
Worldwide in US$ Thousand: 2020 to 2027 II-48
Historic Demand in US$ Thousand: 2012 to 2019 II-49
Percentage by Region/Country: 2012 VS 2020 VS 2027 II-50
Forecasts by Region/Country in US$ Thousand: 2020 to 2027 II-51
Region/Country in US$ Thousand: 2012 to 2019 II-52
Region/Country: 2012 VS 2020 VS 2027 II-53
Region/Country in US$ Thousand: 2020 to 2027 II-54
Region/Country in US$ Thousand: 2012 to 2019 II-55
in Percentage by Region/Country: 2012 VS 2020 VS 2027 II-56
and Forecasts in US$ Thousand by Region/Country: 2020 to 2027 II-57
Historic Review by Region/Country in US$ Thousand: 2012 to 2019 II-58
Distribution by Region/Country: 2012 VS 2020 VS 2027 II-59
Worldwide in US$ Thousand by Region/Country: 2020 to 2027 II-60
US$ Thousand by Region/Country: 2012 to 2019 II-61
Percentage by Region/Country: 2012 VS 2020 VS 2027 II-62
US$ Thousand: 2020 to 2027 II-63
Region/Country in US$ Thousand: 2012 to 2019 II-64
Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 II-65
Estimates & Forecasts in US$ Thousand by Region/Country:
2020-2027 II-66
Analysis in US$ Thousand by Region/Country: 2012-2019 II-67
by Region/Country: 2012 VS 2020 VS 2027 II-68
Worldwide in US$ Thousand by Region/Country: 2020-2027 II-69
in US$ Thousand by Region/Country: 2012-2019 II-70
by Region/Country: 2012 VS 2020 VS 2027 II-71
Demand Forecasts in US$ Thousand by Region/Country: 2020-2027 II-72
Analysis in US$ Thousand by Region/Country: 2012-2019 II-73
Sales by Region/Country: 2012 VS 2020 VS 2027 II-74
Market Overview III-1
Exhibit 17: Healthcare Spending as a % of GDP in the US: 2010-2020 III-2
COVID-19 Pandemic: US Emerges as a Major Market for COVID-19 Tests III-2
Market Analytics III-4
Table 37: United States Clinical Microbiology Instruments and
Reagents Market Estimates and Projections in US$ Thousand by
Product: 2020 to 2027 III-4
in the United States by Product: A Historic Review in US$
Thousand for 2012-2019 III-5
Reagents Market Share Breakdown by Product: 2012 VS 2020 VS
2027 III-6
Reagents Market Estimates and Projections in US$ Thousand by
Disease Area: 2020 to 2027 III-7
in the United States by Disease Area: A Historic Review in US$
Thousand for 2012-2019 III-8
Reagents Market Share Breakdown by Disease Area: 2012 VS 2020
VS 2027 III-9
Reagents Latent Demand Forecasts in US$ Thousand by End-Use:
2020 to 2027 III-10
Historic Demand Patterns in the United States by End-Use in US$
Thousand for 2012-2019 III-11
Share Breakdown in the United States by End-Use: 2012 VS 2020
VS 2027 III-12
Table 46: Canadian Clinical Microbiology Instruments and
Reagents Market Estimates and Forecasts in US$ Thousand by
Product: 2020 to 2027 III-13
Reagents Historic Market Review by Product in US$ Thousand:
2012-2019 III-14
in Canada: Percentage Share Breakdown of Sales by Product for
2012, 2020, and 2027 III-15
Reagents Market Estimates and Forecasts in US$ Thousand by
Disease Area: 2020 to 2027 III-16
Reagents Historic Market Review by Disease Area in US$
Thousand: 2012-2019 III-17
in Canada: Percentage Share Breakdown of Sales by Disease Area
for 2012, 2020, and 2027 III-18
Reagents Market Quantitative Demand Analysis in US$ Thousand by
End-Use: 2020 to 2027 III-19
in Canada: Summarization of Historic Demand Patterns in US$
Thousand by End-Use for 2012-2019 III-20
Reagents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 III-21
Market Overview III-22
Covid-19 Testing Market in Japan III-22
Demographics Drive Market Growth III-22
Exhibit 18: Breakdown of Population by Age Group in Japan:
2010, 2020, and 2025 III-23
Market Analytics III-24
Table 55: Japanese Market for Clinical Microbiology Instruments
and Reagents: Annual Sales Estimates and Projections in US$
Thousand by Product for the Period 2020-2027 III-24
in Japan: Historic Sales Analysis in US$ Thousand by Product
for the Period 2012-2019 III-25
Reagents Market Share Analysis by Product: 2012 VS 2020 VS 2027 III-26
and Reagents: Annual Sales Estimates and Projections in US$
Thousand by Disease Area for the Period 2020-2027 III-27
in Japan: Historic Sales Analysis in US$ Thousand by Disease
Area for the Period 2012-2019 III-28
Reagents Market Share Analysis by Disease Area: 2012 VS 2020 VS
2027 III-29
Microbiology Instruments and Reagents in US$ Thousand by
End-Use: 2020 to 2027 III-30
Reagents Market in US$ Thousand by End-Use: 2012-2019 III-31
Share Shift in Japan by End-Use: 2012 VS 2020 VS 2027 III-32
Market Overview III-33
Covid-19 Testing Market III-33
Market Analytics III-34
Table 64: Chinese Clinical Microbiology Instruments and
Reagents Market Growth Prospects in US$ Thousand by Product for
the Period 2020-2027 III-34
Historic Market Analysis in China in US$ Thousand by Product:
2012-2019 III-35
Reagents Market by Product: Percentage Breakdown of Sales for
2012, 2020, and 2027 III-36
Reagents Market Growth Prospects in US$ Thousand by Disease
Area for the Period 2020-2027 III-37
Historic Market Analysis in China in US$ Thousand by Disease
Area: 2012-2019 III-38
Reagents Market by Disease Area: Percentage Breakdown of Sales
for 2012, 2020, and 2027 III-39
and Reagents in US$ Thousand by End-Use: 2020 to 2027 III-40
Review in China in US$ Thousand by End-Use: 2012-2019 III-41
Reagents Market Share Breakdown by End-Use: 2012 VS 2020 VS
2027 III-42
Market Overview III-43
COVID-19 Pandemic Propels Demand III-43
Growth in Clinical Diagnostics Automation III-43
Rise in Automated, and Rapid Tests in Clinical Applications III-44
Ageing Demography: An Opportunity Indicator III-45
Market Analytics III-46
Table 73: European Clinical Microbiology Instruments and
Reagents Market Demand Scenario in US$ Thousand by
Region/Country: 2020-2027 III-46
in Europe: A Historic Market Perspective in US$ Thousand by
Region/Country for the Period 2012-2019 III-47
Reagents Market Share Shift by Region/Country: 2012 VS 2020 VS
2027 III-48
Reagents Market Estimates and Forecasts in US$ Thousand by
Product: 2020-2027 III-49
in Europe in US$ Thousand by Product: A Historic Review for the
Period 2012-2019 III-50
Reagents Market Share Breakdown by Product: 2012 VS 2020 VS
2027 III-51
Reagents Market Estimates and Forecasts in US$ Thousand by
Disease Area: 2020-2027 III-52
in Europe in US$ Thousand by Disease Area: A Historic Review
for the Period 2012-2019 III-53
Reagents Market Share Breakdown by Disease Area: 2012 VS 2020
VS 2027 III-54
Reagents Addressable Market Opportunity in US$ Thousand by
End-Use: 2020-2027 III-55
in Europe: Summarization of Historic Demand in US$ Thousand by
End-Use for the Period 2012-2019 III-56
Reagents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 III-57
Table 85: Clinical Microbiology Instruments and Reagents Market
in France by Product: Estimates and Projections in US$ Thousand
for the Period 2020-2027 III-58
Historic Market Scenario in US$ Thousand by Product: 2012-2019 III-59
Market Share Analysis by Product: 2012 VS 2020 VS 2027 III-60
in France by Disease Area: Estimates and Projections in US$
Thousand for the Period 2020-2027 III-61
Historic Market Scenario in US$ Thousand by Disease Area:
2012-2019 III-62
Market Share Analysis by Disease Area: 2012 VS 2020 VS 2027 III-63
Quantitative Demand Analysis in France in US$ Thousand by
End-Use: 2020-2027 III-64
Historic Market Review in US$ Thousand by End-Use: 2012-2019 III-65
Market Share Analysis: A 17-Year Perspective by End-Use for
2012, 2020, and 2027 III-66
Table 94: Clinical Microbiology Instruments and Reagents Market
in Germany: Recent Past, Current and Future Analysis in US$
Thousand by Product for the Period 2020-2027 III-67
Historic Market Analysis in US$ Thousand by Product: 2012-2019 III-68
Market Share Breakdown by Product: 2012 VS 2020 VS 2027 III-69
in Germany: Recent Past, Current and Future Analysis in US$
Thousand by Disease Area for the Period 2020-2027 III-70
Historic Market Analysis in US$ Thousand by Disease Area:
2012-2019 III-71
Market Share Breakdown by Disease Area: 2012 VS 2020 VS 2027 III-72
Market in Germany: Annual Sales Estimates and Forecasts in US$
Thousand by End-Use for the Period 2020-2027 III-73
Reagents Market in Retrospect in US$ Thousand by End-Use:
2012-2019 III-74
Market Share Distribution in Germany by End-Use: 2012 VS 2020
VS 2027 III-75
Table 103: Italian Clinical Microbiology Instruments and
Reagents Market Growth Prospects in US$ Thousand by Product for
the Period 2020-2027 III-76
Historic Market Analysis in Italy in US$ Thousand by Product:
2012-2019 III-77
Reagents Market by Product: Percentage Breakdown of Sales for
2012, 2020, and 2027 III-78
Reagents Market Growth Prospects in US$ Thousand by Disease
Area for the Period 2020-2027 III-79
Historic Market Analysis in Italy in US$ Thousand by Disease
Area: 2012-2019 III-80
Reagents Market by Disease Area: Percentage Breakdown of Sales
for 2012, 2020, and 2027 III-81
and Reagents in US$ Thousand by End-Use: 2020 to 2027 III-82
Market Review in Italy in US$ Thousand by End-Use: 2012-2019 III-83
Reagents Market Share Breakdown by End-Use: 2012 VS 2020 VS
2027 III-84
Table 112: United Kingdom Market for Clinical Microbiology
Instruments and Reagents: Annual Sales Estimates and
Projections in US$ Thousand by Product for the Period 2020-2027 III-85
Market in the United Kingdom: Historic Sales Analysis in US$
Thousand by Product for the Period 2012-2019 III-86
Reagents Market Share Analysis by Product: 2012 VS 2020 VS 2027 III-87
Instruments and Reagents: Annual Sales Estimates and
Projections in US$ Thousand by Disease Area for the Period
2020-2027 III-88
Market in the United Kingdom: Historic Sales Analysis in US$
Thousand by Disease Area for the Period 2012-2019 III-89
Reagents Market Share Analysis by Disease Area: 2012 VS 2020 VS
2027 III-90
Clinical Microbiology Instruments and Reagents in US$ Thousand
by End-Use: 2020 to 2027 III-91
Reagents Market in US$ Thousand by End-Use: 2012-2019 III-92
Market Share Shift in the United Kingdom by End-Use: 2012 VS
2020 VS 2027 III-93
Table 121: Spanish Clinical Microbiology Instruments and
Reagents Market Estimates and Forecasts in US$ Thousand by
Product: 2020 to 2027 III-94
Reagents Historic Market Review by Product in US$ Thousand:
2012-2019 III-95
Market in Spain: Percentage Share Breakdown of Sales by Product
for 2012, 2020, and 2027 III-96
Reagents Market Estimates and Forecasts in US$ Thousand by
Disease Area: 2020 to 2027 III-97
Reagents Historic Market Review by Disease Area in US$
Thousand: 2012-2019 III-98
Market in Spain: Percentage Share Breakdown of Sales by Disease
Area for 2012, 2020, and 2027 III-99
Reagents Market Quantitative Demand Analysis in US$ Thousand by
End-Use: 2020 to 2027 III-100
Market in Spain: Summarization of Historic Demand Patterns in
US$ Thousand by End-Use for 2012-2019 III-101
Reagents Market Share Analysis by End-Use: 2012 VS 2020 VS 2027 III-102
Table 130: Russian Clinical Microbiology Instruments and
Reagents Market Estimates and Projections in US$ Thousand by
Product: 2020 to 2027 III-103
Market in Russia by Product: A Historic Review in US$ Thousand
for 2012-2019 III-104
Reagents Market Share Breakdown by Product: 2012 VS 2020 VS
2027 III-105
Reagents Market Estimates and Projections in US$ Thousand by
Disease Area: 2020 to 2027 III-106
Market in Russia by Disease Area: A Historic Review in US$
Thousand for 2012-2019 III-107
Reagents Market Share Breakdown by Disease Area: 2012 VS 2020
VS 2027 III-108
Read the full report: https://www.reportlinker.com/p05957366/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
Artificial Intelligence
Lucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024
![lucinity’s-ai-innovation-recognized-at-microsoft’s-prestigious-global-partner-awards-2024](https://roboticulized.com/wp-content/uploads/2024/06/150829-lucinitys-ai-innovation-recognized-at-microsofts-prestigious-global-partner-awards-2024.jpg)
REYKJAVIK, Iceland, June 28, 2024 /PRNewswire/ — Lucinity has been recognized as a finalist in the AI Innovation category at the prestigious Microsoft Global Partner Awards 2024, recognizing its breakthrough AI solution and contribution to financial security through its collaboration with Microsoft.
Lucinity beat more than 4,700 companies to be named a finalist at the annual Microsoft Global Partner Awards, which highlights Lucinity’s achievements as a Microsoft partner in optimizing business processes, improving customer experiences, and opening new pathways for digital transformation.
This achievement comes in addition to winning two prestigious awards at Microsoft Partner Awards 2024 last month, including Partner of the Year – Iceland, and the Sustainability and Social Impact award.
The accolade recognizes Lucinity’s significant advancements in AI for financial crime operations, particularly through their AI-powered copilot, Luci. This innovative solution utilizes Microsoft Azure OpenAI technology to integrate advanced generative AI into financial crime investigations and regulatory compliance, optimizing processes and saving significant time and resources for financial institutions.
The Lucinity platform streamlines compliance, provides instant insights, and reduces typical investigation times from three hours to just 30 minutes. The technology can also save financial institutions an estimated $100 million in productivity savings, as well as savings in training and recruitment.
Microsoft comments on Lucinity’s award recognition, saying “Financial crime profoundly impacts our global community, with far-reaching economic, security, and social implications. It can harm a country’s reputation and increase exposure to criminal activities, emphasizing the critical need for robust anti-money laundering initiatives and persistent vigilance. Lucinity, with their innovative AI solutions, has really tried to combat this huge global challenge. They use ‘Human AI’ to enhance financial crime prevention, combining AI with human expertise for efficient, user-friendly solutions. Additionally, Lucinity has developed a tool called Luci, an AI-powered copilot that helps transform financial crime prevention from a process that took hours to one that takes minutes.”
“Being recognized as a finalist at the Microsoft Global Partner Awards is validation of our impactful collaboration with Microsoft in financial crime operations. Our partnership has been pivotal for our innovations, enabling us to use Azure OpenAI to bring tools like Luci to life and deliver impactful results for our clients,” says Guðmundur Kristjánsson, Founder & CEO of Lucinity.
Contact:Name: Celina PabloEmail: [email protected]: +354 792 4321
Logo: https://mma.prnewswire.com/media/2208676/4669079/Lucinity_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lucinitys-ai-innovation-recognized-at-microsofts-prestigious-global-partner-awards-2024-302186091.html
Artificial Intelligence
Asia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
![asia-pacific-view:-foreigners-looking-for-the-most-practical-smart-technology-at-the-2024-world-intelligence-expo](https://roboticulized.com/wp-content/uploads/2024/06/150827-asia-pacific-view-foreigners-looking-for-the-most-practical-smart-technology-at-the-2024-world-intelligence-expo.jpg)
BEIJING, June 28, 2024 /PRNewswire/ — Bionic robots that speak both Chinese and English can have the same skin and nails as humans? A flying car powered solely by wind can have a maximum payload of 160 kg? A smart wheelchair can control its operation with just the “mind”? Kevin and Daria, two foreign bloggers, have experienced during the World Intelligence Expo held in Tianjin how the artificial intelligence can empower people’s future lives in industries such as technology, trade, logistics and cultural tourism.
With the theme of “Intelligent Travel Empowering Future”, the Expo integrates exhibitions, experiences and events, attracting more than 550 exhibitors and institutions from all over the world, including more than 70 well-known enterprises such as Huawei, Alibaba, Baidu and Danfoss, and 57 universities and research institutions such as Peking University, Tsinghua University, Nankai University and Tianjin University. The Expo set up 10 major themes such as artificial intelligence, intelligent networked vehicles, intelligent manufacturing and robots, covering the frontier hot spots of the intelligent industry. A number of cutting-edge new technologies, new products, and new experiences from all over the world were showcased centrally, reminding people that technology will completely change the lifestyles in the future.
At the exhibition site, various intelligent robot products such as humanoid robots, bionic robots, and intelligent robot dogs interact with the audience on the spot. They are no longer fantasies in science fiction or movies, but play an important role in monitoring, rescue, cultural tourism and other fields. In the low-altitude economic exhibition area, a number of drones, flying vehicles, and aerospace technology companies collectively display advanced technology products. A low-altitude aircraft shaped like a helicopter brought by the German company Tensor can independently complete cargo transportation, takeoff and landing according to pre-set routes according to the instructions. Robotic arms incorporating technologies such as 5G, IoT, edge computing, rocker robotics, and artificial intelligence can shoot high-frame-rate video and support autofocus, achieving effects that cannot be achieved in traditional shooting modes. Viewers can also have more novel experiences with the help of smart technology.
The Expo also hosted three major events such as the Asia-Pacific Robotics World Cup Tianjin International Invitational, the World Intelligent Driving Challenge, and the International Intelligent Sports Conference. A number of technological achievements and innovative applications were demonstrated in the competitions. For exhibiting companies, this Expo is also an opportunity to further promote the transformation of enterprises to information technology and digitalization, and will also bring huge business opportunities.
Contact: Guo RanPhone: 008610-68332663Email: [email protected]
Video: https://www.youtube.com/watch?v=VjjzurfN_r0 Logo: https://mma.prnewswire.com/media/2451195/logo_Asia_Pacific_View_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/asia-pacific-view-foreigners-looking-for-the-most-practical-smart-technology-at-the-2024-world-intelligence-expo-302186046.html
Artificial Intelligence
Tech Companies Leading the Charge in the Transformative AI Era
![tech-companies-leading-the-charge-in-the-transformative-ai-era](https://roboticulized.com/wp-content/uploads/2024/06/150825-tech-companies-leading-the-charge-in-the-transformative-ai-era.png)
USA News Group Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, June 28, 2024 /PRNewswire/ — USA News Group – The world is changing rapidly thanks to artificial intelligence (AI), with what’s being called the Transformative AI era which comes with great benefits and also potential dangers. The economic impacts are global, with a new report from The Bank for International Settlements (BIS) urging central banks to adapt rapidly to AI advances. Now it’s become apparent how important it is for companies to understand how to harness the full potential of GenAI to secure strategic revenue growth in the coming years. The surge of AI’s usefulness is accelerating innovation in R&D, while behind the scenes tech companies are advancing the infrastructure required to keep this revolution going, including new developments from Avant Technologies Inc. (OTCQB: AVAI), Accenture plc (NYSE: ACN), Cloudflare, Inc. (NYSE: NET), Alphabet Inc. (NASDAQ: GOOG, GOOGL), and Amazon.com, Inc. (NASDAQ: AMZN).
Known for pioneering advancements in AI, Avant Technologies Inc. (OTCQB: AVAI) has persistently refined and expanded its premier offering, Avant AI™. This sophisticated AI platform, celebrated for its machine learning and deep learning capabilities, is the culmination of Avant’s efforts to deliver unprecedented and cost-effective compute infrastructure that unlocks the full potential of AI and ushers in a new era of technological advancement.
“There is a real unmet need as rapid growth across the entirety of the AI and big data industries is outpacing the necessary infrastructure for an industry that demands exponential power and capacity while remaining cost effective,” said Avant’s CEO William Hisey in a recent address of progress on AI supercomputer-driven data centers. “Avant’s ‘edge-native’ approach doesn’t rely on cloud-based services so we can offer AI and big data companies many advantages over the more familiar ‘cloud-native’ approach, including, reduced latency, improved security and privacy, increased scalability, and reduced costs.”
In a recent strategic development, Avant entered into a Binding Letter of Intent (BLOI) with Flow Wave, LLC (FW), a prominent Florida-based firm specializing in immersible computer server technology. This agreement allows Avant to acquire up to 50 cutting-edge immersible computer servers from FW, in a transaction valued at $50 million.
“By integrating proprietary machine learning algorithms with open-source innovations into these servers, Avant is developing a highly intelligent system designed to optimize resource allocation, enhance performance, and drive unprecedented levels of efficiency and automation,” said Hisey. “This marks the beginning of a new era for Avant Technologies, positioning us at the forefront of the supercomputer-driven data center industry and setting new standards for managing and storing AI applications.”
Flow Wave Immersible AI Supercomputer Servers are engineered for demanding AI and machine learning applications, delivering powerful processing capabilities that accelerate data analysis. Their cutting-edge cooling system is both energy-efficient and cost-effective, reducing environmental impact. These servers’ compact design facilitates easy installation in space-constrained data centers, and their robust construction ensures longevity and lower maintenance requirements.
In response to digital era challenges, Avant intends to acquire up to 50 of these high-performance servers. Their superior cooling technology boosts performance while conserving energy, aligning with Avant’s goal of providing top-tier AI infrastructure and maximizing efficiency. Additional details about the acquisition will be shared once the final agreement is secured.
In Q3 2024, Accenture plc (NYSE: ACN) brought in over $900 million in new Generative AI bookings, for a total of $2 billion fiscal year-to-date. Despite missing its overall earnings targets, the market responded by sending its shares upward.
“We achieved strong new bookings of over $21 billion, up 22% over last year, and continued to accelerate our strategy to be the reinvention partner of choice, with another 23 clients with quarterly bookings of over $100 million, bringing the total of such bookings to 92 year-to-date,” said Julie Sweet, Chair and CEO of Accenture. “We also achieved two significant milestones this quarter — with $2 billion in Generative AI sales year-to-date and $500 million in revenue year-to-date — which demonstrate our early lead in this critical technology.”
Back in May, Accenture took steps to help its clients to scale their Generative AI responsibly.
“Clients are eager to embrace the potential of generative AI, and we are ready to help them build responsible AI into every use,” said Sweet. “We do this for ourselves, and we can use that example to help our clients find success faster. Our focus is to enable our clients to innovate AI safely and be ready to seize the opportunities that AI will bring in the decades ahead.”
Recently, the cloud-based security solution provider Cloudflare, Inc. (NYSE: NET) unveiled the general availability of its AI Gateway platform. Marketed as a comprehensive interface for managing and scaling generative AI workloads, the platform has transitioned from its beta phase, which started in September 2023, to full client use after successfully handling over 500 million requests.
This launch coincides with Cloudflare’s announcement of a partnership with Hugging Face, a leading platform for AI developers. The collaboration offers a one-click global deployment for AI applications via the Workers AI platform, now also generally available. As the first serverless inference partner integrated on the Hugging Face Hub, this allows developers to deploy AI models quickly, easily, and cost-effectively on a global scale, without the need for managing infrastructure or paying for unused compute capacity.
“Workers AI is one of the most affordable and accessible solutions to run inference,” said Matthew Prince, CEO and co-founder, Cloudflare. “With Hugging Face and Cloudflare both deeply aligned in our efforts to democratize AI in a simple, affordable way, we’re giving developers the freedom and agility to choose a model and scale their AI apps from zero to global in an instant.”
In the education space, Alphabet Inc. (NASDAQ: GOOG, GOOGL) through Google, is bringing new AI tools to Google Workspace for teen students using their school accounts to help them learn responsibly and confidently in an AI-first future, and empowering educators with new tools to help create great learning experiences.
“In the coming months, we’re making Gemini available to teen students that meet our minimum age requirements while using their Google Workspace for Education accounts in English in over 100 countries around the world, free of charge for all education institutions,” said Google in a blog post. “To ensure schools are always in control, Gemini will be off by default for teens until admins choose to turn it on as an Additional Service in the Admin console.”
Google has also developed a number of resources and trainings to help students, parents and educators use generative AI tools responsibly and effectively, including a video on how teens can responsibly use AI while learning.
After recently hitting a $2-trillion valuation, Amazon.com, Inc. (NASDAQ: AMZN) continues to be a big player in the AI space. Now it’s reportedly working on its own AI chatbot that some say might be smarter than ChatGPT, named Metis, which will generate answers by grabbing info from the internet.
Metis is driven by an internal Amazon AI model known as Olympus, drawing inspiration from Greek mythology. According to sources, Olympus is a more advanced version of Amazon’s publicly available Titan model.
Amazon’s CEO Andy Jassy has noted that nearly every division within the company is engaged in some form of AI project. As a pioneer in cloud computing, Amazon has been developing machine learning, a subset of AI, for many years. Jassy recently announced that Amazon’s AI initiatives are projected to generate over $1 billion in annual revenue, with expectations of driving “tens of billions of dollars” in sales in the coming years.
However, Amazon has lagged in the realm of consumer AI assistants. An internal document from last year highlighted that Amazon “does not have a publicly or internally available product that looks and works exactly like ChatGPT.”
According to a source reported by Business Insider, the tentative launch date for Metis is September, right around the time when Amazon is set to host a big Alexa event, although the timeline could still change.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.co.uk/news-releases/tech-companies-leading-the-charge-in-the-transformative-ai-era-302185931.html
-
Artificial Intelligence7 days ago
2024 Tang Prize Laureates Announced: Six Global Visionaries to Be Honored in Taiwan This September
-
Artificial Intelligence4 days ago
Relativity Announces General Availability Date for its Generative AI-Powered Review Solution at Relativity Fest London
-
Artificial Intelligence6 days ago
Juniper Biologics Expands Distribution Rights for Caris Life Sciences’ Molecular Profiling in the Middle East and Africa
-
Artificial Intelligence4 days ago
SKAN, the Wellcome Sanger Institute and University of Newcastle to study early stem cell mutations in rare blood disorder
-
Artificial Intelligence4 days ago
COMPREDICT Secures $15M Series B Funding Round Led by Woven Capital
-
Artificial Intelligence4 days ago
AI Revolution Accelerates: North American Tech Companies Lead Amid Regulatory Changes
-
Artificial Intelligence4 days ago
Workers embrace AI and prioritise skills growth amid rising workloads and an accelerating pace of change: PwC 2024 Global Workforce Hopes & Fears Survey
-
Artificial Intelligence5 days ago
AI Vulnerability Scanning market Size to Grow USD 7,574.30 Million by 2030 at a CAGR of 13.52% | Valuates Reports